Translational Development Acquisition Stock Performance
| TDAC Stock | USD 10.46 0.01 0.1% |
Translational Development has a performance score of 8 on a scale of 0 to 100. The entity has a beta of -0.0093, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Translational Development are expected to decrease at a much lower rate. During the bear market, Translational Development is likely to outperform the market. Translational Development right now has a risk of 0.14%. Please validate Translational Development sortino ratio, potential upside, and the relationship between the jensen alpha and maximum drawdown , to decide if Translational Development will be following its existing price patterns.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Translational Development Acquisition are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of rather sound basic indicators, Translational Development is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.19 | Five Day Return 0.19 | Year To Date Return 4.7 | Ten Year Return 4.7 | All Time Return 4.7 |
1 | Published on 2025-10-21 005021 - nchmf.gov.vn | 10/20/2025 |
2 | Will Translational Development Acquisition Corp. Equity Warrant stock continue dividend increases - Global Markets AI Enhanced Trade Execution Alerts - fcp.pa.g... | 11/06/2025 |
3 | Can Translational Development Acquisition Corp. stock sustain free cash flow growth - Portfolio Risk Report Weekly Watchlist of Top Performers - newser.com | 11/10/2025 |
4 | How Translational Development Acquisition Corp. Equity Warrant stock performs in weak economy - Weekly Trade Recap Risk Controlled Swing Alerts - newser.com | 11/14/2025 |
5 | Will Translational Development Acquisition Corp. Equity Warrant stock continue dividend increases - IPO Watch Short-Term Swing Trade Alerts - newser.com | 11/17/2025 |
6 | Is Translational Development Acquisition Corp. stock overvalued by current metrics - July 2025 Trends Stepwise Trade Signal Guides - newser.com | 11/20/2025 |
7 | Can Translational Development Acquisition Corp. stock deliver consistent earnings growth - July 2025 Spike Watch Daily Market Momentum Tracking - Newser | 12/02/2025 |
8 | Is Translational Development Acquisition Corp. stock a defensive play in 2025 - Gold Moves Free Fast Gain Swing Trade Alerts - DonanmHaber | 12/19/2025 |
| Begin Period Cash Flow | 2021.00 | |
| Total Cashflows From Investing Activities | -174.2 M |
Translational | Build AI portfolio with Translational Stock |
Translational Development Relative Risk vs. Return Landscape
If you would invest 1,036 in Translational Development Acquisition on September 25, 2025 and sell it today you would earn a total of 10.00 from holding Translational Development Acquisition or generate 0.97% return on investment over 90 days. Translational Development Acquisition is currently generating 0.0153% in daily expected returns and assumes 0.1362% risk (volatility on return distribution) over the 90 days horizon. In different words, 1% of stocks are less volatile than Translational, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Translational Development Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Translational Development's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Translational Development Acquisition, and traders can use it to determine the average amount a Translational Development's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TDAC |
Based on monthly moving average Translational Development is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Translational Development by adding it to a well-diversified portfolio.
Translational Development Fundamentals Growth
Translational Stock prices reflect investors' perceptions of the future prospects and financial health of Translational Development, and Translational Development fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Translational Stock performance.
| Current Valuation | 220.39 M | ||||
| Shares Outstanding | 17.25 M | ||||
| Price To Book | 1.30 X | ||||
| EBITDA | (71.01 K) | ||||
| Net Income | (71.01 K) | ||||
| Cash And Equivalents | 972.79 K | ||||
| Cash Per Share | 0.13 X | ||||
| Total Debt | 6.11 T | ||||
| Debt To Equity | 1.01 % | ||||
| Current Ratio | 0.19 X | ||||
| Book Value Per Share | (0.14) X | ||||
| Cash Flow From Operations | (851.45 K) | ||||
| Earnings Per Share | (0.03) X | ||||
| Market Capitalization | 219.95 M | ||||
| Total Asset | 175 M | ||||
| Retained Earnings | (5.6 M) | ||||
| Working Capital | 439.93 K | ||||
About Translational Development Performance
By analyzing Translational Development's fundamental ratios, stakeholders can gain valuable insights into Translational Development's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Translational Development has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Translational Development has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year |
Things to note about Translational Development performance evaluation
Checking the ongoing alerts about Translational Development for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Translational Development help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Translational Development has high likelihood to experience some financial distress in the next 2 years | |
| Translational Development Acquisition currently holds 6.11 T in liabilities with Debt to Equity (D/E) ratio of 1.01, which is about average as compared to similar companies. Translational Development has a current ratio of 0.19, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Translational Development's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (71.01 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Translational Development Acquisition currently holds about 972.79 K in cash with (851.45 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.13. | |
| Translational Development has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Is Translational Development Acquisition Corp. stock a defensive play in 2025 - Gold Moves Free Fast Gain Swing Trade Alerts - DonanmHaber |
- Analyzing Translational Development's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Translational Development's stock is overvalued or undervalued compared to its peers.
- Examining Translational Development's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Translational Development's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Translational Development's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Translational Development's stock. These opinions can provide insight into Translational Development's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Translational Stock analysis
When running Translational Development's price analysis, check to measure Translational Development's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Translational Development is operating at the current time. Most of Translational Development's value examination focuses on studying past and present price action to predict the probability of Translational Development's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Translational Development's price. Additionally, you may evaluate how the addition of Translational Development to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |